SG11201807148RA - Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions - Google Patents
Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositionsInfo
- Publication number
- SG11201807148RA SG11201807148RA SG11201807148RA SG11201807148RA SG11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA
- Authority
- SG
- Singapore
- Prior art keywords
- epha2
- docetaxel
- international
- massachusetts
- immunoliposomes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662309222P | 2016-03-16 | 2016-03-16 | |
US201662322940P | 2016-04-15 | 2016-04-15 | |
US201662338052P | 2016-05-18 | 2016-05-18 | |
US201662419012P | 2016-11-08 | 2016-11-08 | |
US201762464538P | 2017-02-28 | 2017-02-28 | |
PCT/US2017/022624 WO2017161067A1 (en) | 2016-03-16 | 2017-03-16 | Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807148RA true SG11201807148RA (en) | 2018-09-27 |
Family
ID=58461461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807148RA SG11201807148RA (en) | 2016-03-16 | 2017-03-16 | Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions |
Country Status (12)
Country | Link |
---|---|
US (1) | US20180021294A1 (ko) |
EP (1) | EP3429629A1 (ko) |
JP (1) | JP2019508434A (ko) |
KR (1) | KR20180121904A (ko) |
CN (1) | CN109310782A (ko) |
AU (1) | AU2017232632A1 (ko) |
BR (1) | BR112018068000A2 (ko) |
CA (1) | CA3016455A1 (ko) |
IL (1) | IL261276A (ko) |
SG (1) | SG11201807148RA (ko) |
TW (1) | TW201804987A (ko) |
WO (1) | WO2017161067A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012759A2 (en) * | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
CA3016676A1 (en) * | 2016-03-16 | 2017-09-21 | The Regents Of The University Of California | Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof |
WO2018160794A1 (en) | 2017-03-01 | 2018-09-07 | Merrimack Pharmaceuticals, Inc. | Epha2-targeted docetaxel -generating liposomes in combination with an agent that impedes regulatory t cell activity for treating cancer |
EP4349857A1 (en) | 2021-05-25 | 2024-04-10 | Vaxcell-Bio | Monobody-based chimeric antigen receptor and immune cell including same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
DE69638269D1 (de) | 1995-06-14 | 2010-11-18 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US20050153923A1 (en) * | 2003-12-04 | 2005-07-14 | Kinch Michael S. | Targeted drug delivery using EphA2 or EphA4 binding moieties |
CA2821167C (en) | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
WO2012012759A2 (en) * | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
CN103479578B (zh) * | 2012-06-14 | 2016-08-03 | 沈阳药科大学 | 一种马来酸匹杉琼的脂质体制剂及其制备工艺 |
JP6294456B2 (ja) * | 2013-03-13 | 2018-03-14 | マリンクロッド エルエルシー | 修飾されたドセタキセルリポソーム製剤 |
-
2017
- 2017-03-16 EP EP17714967.1A patent/EP3429629A1/en not_active Withdrawn
- 2017-03-16 SG SG11201807148RA patent/SG11201807148RA/en unknown
- 2017-03-16 TW TW106108755A patent/TW201804987A/zh unknown
- 2017-03-16 BR BR112018068000A patent/BR112018068000A2/pt not_active Application Discontinuation
- 2017-03-16 WO PCT/US2017/022624 patent/WO2017161067A1/en active Application Filing
- 2017-03-16 AU AU2017232632A patent/AU2017232632A1/en not_active Abandoned
- 2017-03-16 KR KR1020187025716A patent/KR20180121904A/ko unknown
- 2017-03-16 JP JP2018546488A patent/JP2019508434A/ja active Pending
- 2017-03-16 CA CA3016455A patent/CA3016455A1/en not_active Abandoned
- 2017-03-16 US US15/460,280 patent/US20180021294A1/en not_active Abandoned
- 2017-03-16 CN CN201780015505.7A patent/CN109310782A/zh active Pending
-
2018
- 2018-08-21 IL IL261276A patent/IL261276A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017161067A1 (en) | 2017-09-21 |
KR20180121904A (ko) | 2018-11-09 |
CN109310782A (zh) | 2019-02-05 |
US20180021294A1 (en) | 2018-01-25 |
AU2017232632A1 (en) | 2018-09-13 |
JP2019508434A (ja) | 2019-03-28 |
TW201804987A (zh) | 2018-02-16 |
IL261276A (en) | 2018-10-31 |
EP3429629A1 (en) | 2019-01-23 |
BR112018068000A2 (pt) | 2019-02-05 |
CA3016455A1 (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201807148RA (en) | Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
SG11201811237WA (en) | Combination therapies | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201407349UA (en) | Proliposomal testosterone formulations | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |